LKFT
Lakefront Biotherapeutics N.V.
LKFT has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over LKFT overall, supported by stronger modeled upside and stronger fundamentals.
LKFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
LKFT's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LKFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.2x | $32.15 | -5.2% |
| Current | 3.4x | $33.93 | — |
| Fair | 3.5x | $35.61 | +5% |
| Expensive | 5.1x | $51.37 | +51% |
Historical ranges are pointers, not guarantees.
LKFT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LKFT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LKFT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LKFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$0.67 | +$0.54 |
| Q3 2023 | -$0.72 | -820% |
| Q2 2023 | -$0.79 | +$0.58 |
LKFT has the edge over LLY in the latest year-over-year earnings comparison.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LKFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.5M | -81% |
| Q1 2026 | $7.2M | -91% |
| Q4 2025 | $1B | +1093% |
| Q3 2025 | $79.1M | +19% |
| Q2 2025 | $72.5M | -16% |
| Q1 2025 | $83.3M | +20% |
| Q3 2024 | $66.5M | -50% |
| Q2 2024 | $86.5M | +30% |
LKFT's revenue is growing: $13M last quarter, down 81% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -359% | -272 points |
| Q1 2026 | -983% | -771 points |
| Q4 2025 | 84% | +192 points |
| Q3 2025 | -59% | +32 points |
| Q2 2025 | -87% | -38 points |
| Q1 2025 | -212% | -159 points |
| Q4 2024 | -107% | N/A |
| Q3 2024 | -91% | -66 points |
LKFT's operating margin was −359% last quarter, down 272 points from the same quarter a year ago, near the bottom of its range since 2017.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LKFT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LKFT on profitability, with a higher operating margin.
LKFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$125.5M |
| Q4 2020 | -$278.6M | -108% |
| Q4 2019 | $3.7B | +$3.8B |
| Q4 2018 | -$65.1M | +$104.2M |
LKFT has burned cash in most quarters: −$219M over the past year, against $3.2B the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
LKFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +4.2M shares |
| 1 year | +6.4% | +4.2M shares |
| 3 years | +6.5% | +4.3M shares |
LKFT has 70M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
LKFT hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LKFT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LKFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
LKFT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LKFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 87.8 | Overbought |
LKFT's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LKFT PE vs Healthcare Sector
| Metric | LKFT | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
| PE % | 39 | 29 | 10 pts above |
LKFT has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LKFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 8.7% above |
| 20 week MA | $29.6 | 15% above |
| 50 week MA | $30.4 | 12% above |
| 100 week MA | $29.6 | 15% above |
| 200 week MA | $32.2 | 5.5% above |
LKFT has climbed back above all five of its weekly moving averages, and it's now 5.5% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
LKFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.4 | $99.3 | -53% |
| 2021 | $99.3 | $55.9 | -44% |
| 2022 | $55.9 | $42.2 | -25% |
| 2023 | $42.2 | $40.7 | -3.7% |
| 2024 | $40.7 | $27.3 | -33% |
| 2025 | $27.3 | $33.0 | +21% |
| 2026 YTD | $33.0 | $33.9 | +2.7% |
LKFT has finished lower in five of the last six years. It's up 2.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LKFT on returns for 2026, with the stronger performance.